Patrys is a publicly-listed company on the Australian Securities Exchange (ASX:PAB).  Our principal focus is on the development of antibody therapies for major market opportunities in the oncology area.  
Patrys has two technology platforms: IgM monoclonal antibodies and suite of nuclear penetrating antibodies for cancer therapy.   

Our principal focus is on the development of antibody therapies for major market opportunities in the oncology area.

Patrys has three drug assets in development across two programs: IgM monoclonal antibodies and Deoxymabs a suite of nuclear-penetrating antibody for cancer therapy.